The Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension
NCT ID: NCT06980922
Last Updated: 2025-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
34 participants
INTERVENTIONAL
2025-06-01
2028-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Does Guilu Erxian Jiao reduce the frequency and severity of low blood pressure during dialysis?
2. Is Guilu Erxian Jiao safe to use in patients receiving hemodialysis?
Researchers will compare standard care plus Guilu ErXian Jiao to standard care alone to see if Guilu Erxian Jiao improves blood pressure stability during dialysis.
Participants will:
1. Take Guilu Erxian Jiao once daily in addition to standard care, or receive standard care alone, for 4 weeks, then switch treatments after a 4-week washout period (crossover design).
2. Undergo follow-up assessments at weeks 2 and 4 after each treatment phase.
3. Have their blood pressure monitored before, during (hourly), and after each dialysis session.
4. Report dialysis-related symptoms such as dizziness and fatigue.
5. Receive routine laboratory tests and safety monitoring throughout the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Gui-Lu-Er-Xian-Jiao-Wan on Intradialytic Hypotension
NCT05517993
Chinese Medicine on Deferring Dialysis Initiation
NCT02194946
Analysis of Influencing Factors of Hypotension in Diabetic Patients Undergoing Dialysis
NCT05325892
The Effects of Resveratrol on the Complications of Patients With Hemodialysis
NCT03352895
Effects of Intradialytic Exercise on Health-related Quality of Life
NCT04990154
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure of more than 20 mmHg or a drop of more than 10 mmHg in mean arterial pressure during hemodialysis, often accompanied by symptoms such as dizziness, nausea, or cramps. The incidence of IDH among dialysis patients is approximately 5% to 30%. Risk factors include advanced age, diabetes, female sex, and high body mass index. IDH can cause premature termination of dialysis sessions, resulting in decreased uremic toxin clearance and increased long-term mortality and complications. Severe IDH may lead to bowel ischemia, stroke, or myocardial infarction.
Common management strategies for IDH include adjusting the dialysis rate, lowering dialysate temperature, avoiding eating during dialysis, and strict sodium intake control. In cases of frequent IDH episodes, drugs such as Midodrine or Vasopressin may be used. However, oral Midodrine can cause side effects such as urinary retention, paresthesia, and pruritus. Its long-term safety in dialysis patients is yet to be confirmed.
According to Traditional Chinese Medicine (TCM), IDH results from spleen and kidney Qi deficiency, requiring tonification of these organs. Guilu Erxian Jiao (GLJ) is a classical formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, commonly used to treat Qi deficiency and hypotension. Clinical experience suggests potential efficacy in reducing IDH frequency, but large-scale trials are lacking.
This trial aims to evaluate the efficacy and safety of GLJ in treating IDH in patients undergoing hemodialysis.
2. Study Design and Methods
This is a randomized, open-label, crossover clinical trial enrolling 34 patients aged over 18 years who receive thrice-weekly hemodialysis for four hours per session and have a history of IDH. Patients are recruited from nephrology and TCM outpatient clinics and the dialysis unit of Keelung Chang Gung Memorial Hospital.
Participants will be randomized 1:1 into two groups. Randomization will be performed using a computer-generated random sequence. Participants will be assigned to groups according to sealed envelopes that indicate their allocation. Group A receives GLJ plus conventional treatment for four weeks, followed by a four-week washout period, then four weeks of conventional treatment alone. Group B follows the reverse sequence.
GLJ (Guilu Erxian Jiao) is administered once daily before meals at a dose of 4 grams for four weeks. The preparation used is Jipin Guilu Baishen San produced by Sun Ten Pharmaceutical Co., Ltd. (License number: 016966).
Data collected include demographic information, medical history, allergy history, family history, medication history, and socioeconomic status. Evaluations include blood pressure measurements before, during, and after dialysis; frequency of IDH episodes; symptoms such as dizziness and fatigue (via VAS score); laboratory parameters (Na, K, Ca, P, BUN, Cr); and adverse events.
Follow-up evaluations occur at weeks 2 and 4 after each treatment phase. Each assessment takes approximately 30 minutes.
3. Participant Safety, Compensation, and Withdrawal Rights
Guilu Erxian Jiao is generally well tolerated. Reported side effects in prior studies include mild dry mouth and constipation. During the study, blood and biochemical parameters will be regularly monitored to detect any possible adverse effects.
If allergic reactions or serious adverse events occur during the trial, the participant will be withdrawn from the study and provided with appropriate medical evaluation and care.
Participants may voluntarily withdraw from the study at any time without providing a reason and without any impact on their standard medical care. Likewise, the principal investigator reserves the right to terminate a participant's involvement or discontinue the trial at any time for safety or administrative reasons.
In case of adverse events or injuries resulting from participation in this study, and if they occur in accordance with the approved protocol, the institution and the principal investigator will be legally responsible for providing necessary compensation. However, no compensation will be provided for anticipated side effects explicitly stated in the study protocol. In addition to compensation, the hospital will also provide professional medical care and consultation at no cost for treating the injury.
4. Data Privacy and Confidentiality
Participant identities will be anonymized using unique study codes, and no personally identifiable information (e.g., name, medical record number) will appear in the case reports or publications. Study data will be securely stored in locked cabinets and password-protected, encrypted folders for at least two years after the end of the study. Only the principal investigator, authorized research team members, auditors, the ethics committee, and regulatory authorities will have access to the original data for monitoring and auditing purposes. The research team is committed to maintaining confidentiality and protecting participants' privacy throughout the study.
5. Statistical Analysis
Sample size calculation was based on previous studies with a significance level of 0.05 and power of 0.99, resulting in a required 28 participants; with an estimated 20% dropout rate, 34 participants will be enrolled.
Statistical analyses include Student's t-test, Chi-square test, ANOVA, and paired t-tests as appropriate. Non-parametric tests will be used if data are not normally distributed. All efficacy analyses will be performed using the intention-to-treat (ITT) principle, including all randomized participants who received at least one dose of study intervention. A one-sided alpha of 0.05 defines statistical significance.
6. IRB Review and Approval This study has been reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital, Keelung Branch (IRB No. 2402010026, Protocol Version 5, approved on 2025/03/12).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Participants in Group A will receive Guilu Erxian Jiao (GLJ) plus usual care for 4 weeks, followed by a 4-week washout period, then 4 weeks of usual care alone.
Guilu Erxian Jiao
A traditional Chinese herbal formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, manufactured by Sun Ten Pharmaceutical Co., Ltd. (License No. 016966). Administered orally at 4 grams per day before meals for 4 weeks.
Group B
Participants in Group B will receive usual care alone for 4 weeks, followed by a 4-week washout period, then 4 weeks of Guilu Erxian Jiao (GLJ) plus usual care.
Guilu Erxian Jiao
A traditional Chinese herbal formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, manufactured by Sun Ten Pharmaceutical Co., Ltd. (License No. 016966). Administered orally at 4 grams per day before meals for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Guilu Erxian Jiao
A traditional Chinese herbal formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, manufactured by Sun Ten Pharmaceutical Co., Ltd. (License No. 016966). Administered orally at 4 grams per day before meals for 4 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing maintenance hemodialysis three times per week, 4 hours per session
* History of intradialytic hypotension (IDH)
* Willing and able to provide written informed consent
Exclusion Criteria
* Severe comorbid illness, such as cancer, stroke, or liver cirrhosis
* Inability to comply with study medication regimen
* Regular use of antihypertensive medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chang Gung Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huan-Hsuan Hsu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Chinese Medicine, Keelung Chang Gung Memorial Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Keelung Chang Gung Memorial Hospital
Keelung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension. Am J Nephrol. 2018;48(5):381-388. doi: 10.1159/000494806. Epub 2018 Nov 13.
Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Culleton BF; Canadian Society of Nephrology Committee for Clinical Practice Guidelines. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-27. doi: 10.1681/ASN.2005121372. No abstract available.
Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. 2015 Mar;26(3):724-34. doi: 10.1681/ASN.2014020222. Epub 2014 Sep 30.
Morfin JA, Fluck RJ, Weinhandl ED, Kansal S, McCullough PA, Komenda P. Intensive Hemodialysis and Treatment Complications and Tolerability. Am J Kidney Dis. 2016 Nov;68(5S1):S43-S50. doi: 10.1053/j.ajkd.2016.05.021.
Flythe JE, Inrig JK, Shafi T, Chang TI, Cape K, Dinesh K, Kunaparaju S, Brunelli SM. Association of intradialytic blood pressure variability with increased all-cause and cardiovascular mortality in patients treated with long-term hemodialysis. Am J Kidney Dis. 2013 Jun;61(6):966-74. doi: 10.1053/j.ajkd.2012.12.023. Epub 2013 Mar 6.
Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG guideline on dialysis strategies. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii5-21. doi: 10.1093/ndt/gfm022. No abstract available.
Mo Y, Liu X, Qin X, Huang J, He Z, Lin J, Hu Q, Cai Y, Liu Z, Wang L. Shenfu injection for intradialytic hypotension: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2014;2014:279853. doi: 10.1155/2014/279853. Epub 2014 Dec 22.
Sands JJ, Usvyat LA, Sullivan T, Segal JH, Zabetakis P, Kotanko P, Maddux FW, Diaz-Buxo JA. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int. 2014 Apr;18(2):415-22. doi: 10.1111/hdi.12138. Epub 2014 Jan 27.
Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, Konner K, Martin-Malo A, Pedrini L, Tattersall J, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii22-44. doi: 10.1093/ndt/gfm019. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202400179A3C601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.